Immunomedics (IMMU) Awarded 2 Small Business Grants from NIH
Up)
Immunomedics, Inc. (Nasdaq: IMMU) has been awarded 3 Small Business Innovation Research (SBIR) grants by the National Institutes of Health (NIH), totaling $2.1 million payable over a period of 2 years. One of the awards can be extended to 3 years with a potential $2.5 million additional funding, if certain goals and milestones are met.
The first award is a Phase I grant for the development of a hematopoietic tumor-targeting humanized antibody conjugated site-specifically with 4 interferon-a2b groups.
The NIH has also awarded the Company a multiyear Phase II grant for the development of F-18 labeled peptides for pretargeted positron-emission tomography, or PET, imaging of pancreatic cancer.
Another multiyear Phase II grant was awarded to support a clinical trial of combined radio- and immunotherapy of aggressive non-Hodgkin's lymphoma (NHL).
The first award is a Phase I grant for the development of a hematopoietic tumor-targeting humanized antibody conjugated site-specifically with 4 interferon-a2b groups.
The NIH has also awarded the Company a multiyear Phase II grant for the development of F-18 labeled peptides for pretargeted positron-emission tomography, or PET, imaging of pancreatic cancer.
Another multiyear Phase II grant was awarded to support a clinical trial of combined radio- and immunotherapy of aggressive non-Hodgkin's lymphoma (NHL).
You May Also Be Interested In
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
- Dr. Reddy’s Labs (RDY) Launches Generic OTC Prevacid (NVS)
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
